Coating a Self-Assembly Nanoconstruct with a Neutrophil Cell Membrane Enables High Specificity for Triple Negative Breast Cancer Treatment
- PMID: 35976626
- DOI: 10.1021/acsabm.2c00614
Coating a Self-Assembly Nanoconstruct with a Neutrophil Cell Membrane Enables High Specificity for Triple Negative Breast Cancer Treatment
Abstract
Breast cancer is one of the most commonly diagnosed cancers in American women. Triple negative breast cancer is among the most advanced and aggressive forms of breast cancer. Treatment options are limited for such cancers, making chemotherapy a convenient and effective treatment. Although these therapies can reduce morbidity and mortality, it is often followed by systemic side effects or relapse. Nanoparticles (NPs) have been considered for drug delivery approaches due to their ability to target various disease sites. Herein, we aim to develop a biomimetic NP construct (cell membrane-cloaked NPs) that exhibits specific affinity with triple negative breast cancer cells. In this regard, we designed biomimetic supramolecular nanoconstructs composed of a poly(vinyl pyrrolidone)-tannic acid (PVP-TA NPs/ PVT NPs) core and biofunctionalized with neutrophil cell membranes (PVT-NEU NPs). In this study, we have synthesized a PVT-NEU NP construct, characterized it, and evaluated it for improved targeting and therapeutic benefits in in vitro and in vivo models. Analysis of PVT-NEU NPs confirms the presence of the core of PVP-TA NPs coated with activated human neutrophil membranes. The study results confirmed that PVT-NEU NPs demonstrated an enhanced interaction and targeting with the tumor cells, thus improving the therapeutic activity of a model therapeutic agent (paclitaxel). Altogether, this study suggests the potential of biomimetic NPs as a promising therapeutic option for targeted drug delivery for advanced-stage breast cancer and other similar diseased conditions.
Keywords: biomimetic nanoparticles; breast cancer treatment; chemotherapy; membrane-cloaked nanoparticles; nanomedicine; nanoparticles; triple negative breast cancer.
Similar articles
-
Erythrocyte-cancer hybrid membrane-coated reduction-sensitive nanoparticles for enhancing chemotherapy efficacy in breast cancer.Biomater Adv. 2023 Aug;151:213456. doi: 10.1016/j.bioadv.2023.213456. Epub 2023 May 9. Biomater Adv. 2023. PMID: 37196459
-
Biomimetic Targeted Theranostic Nanoparticles for Breast Cancer Treatment.Molecules. 2022 Oct 1;27(19):6473. doi: 10.3390/molecules27196473. Molecules. 2022. PMID: 36235009 Free PMC article.
-
Development of Zoledronic Acid-Based Nanoassemblies for Bone-Targeted Anticancer Therapy.ACS Biomater Sci Eng. 2019 May 13;5(5):2343-2354. doi: 10.1021/acsbiomaterials.9b00362. Epub 2019 Apr 8. ACS Biomater Sci Eng. 2019. PMID: 33405784
-
Surface modification potentials of cell membrane-based materials for targeted therapies: a chemotherapy-focused review.Nanomedicine (Lond). 2023 Aug;18(19):1281-1303. doi: 10.2217/nnm-2023-0164. Epub 2023 Sep 27. Nanomedicine (Lond). 2023. PMID: 37753724 Review.
-
Bioactive nanotherapeutic trends to combat triple negative breast cancer.Bioact Mater. 2021 Mar 13;6(10):3269-3287. doi: 10.1016/j.bioactmat.2021.02.037. eCollection 2021 Oct. Bioact Mater. 2021. PMID: 33778204 Free PMC article. Review.
Cited by
-
Supramolecular nanomedicine in the intelligent cancer therapy: recent advances and future.Front Pharmacol. 2024 Oct 11;15:1490139. doi: 10.3389/fphar.2024.1490139. eCollection 2024. Front Pharmacol. 2024. PMID: 39464634 Free PMC article. Review.
-
Convergence of nanomedicine and neutrophils for drug delivery.Bioact Mater. 2024 Jan 27;35:150-166. doi: 10.1016/j.bioactmat.2024.01.022. eCollection 2024 May. Bioact Mater. 2024. PMID: 38318228 Free PMC article.
-
Indocyanine Green-based Glow Nanoparticles Probe for Cancer Imaging.Nanotheranostics. 2023 Apr 9;7(4):353-367. doi: 10.7150/ntno.78405. eCollection 2023. Nanotheranostics. 2023. PMID: 37151801 Free PMC article.
LinkOut - more resources
Research Materials
Miscellaneous